[1] Tan Z , Li M , Kuang X , et al. Clinical implications of hepatitis B surface antigen quantitation in the natural history of chronic hepatitis B virus infection. J Clin Virol, 2014, 59:228-234. [2] Sonneveld MJ , Zoutendijk R , Janssen HLA . Hepatitis B surface antigen monitoring and management of chronic hepatitis B. J Viral Hepat, 2011, 18:449-457. [3] 郜玉峰, 邹桂舟, 叶珺, 等. HBsAg和HBV DNA定量水平与肝纤维化程度的关系. 中华肝脏病杂志, 2015, 23:254-257. [4] Lebda MA , Sadek KM , Abouzed TK , et al. Melatonin mitigates thioacetamide-induced hepatic fibrosis via antioxidant activity and modulation of proinflammatory cytokines and fibrogenic genes. Life Sci, 2017, 1:136-143. [5] 王贵强, 王福生, 成军,等. 慢性乙型肝炎防治指南(2015年版). 中华实验和临床感染病杂志(电子版), 2015, 19:1-18. [6] 中华医学会传染病与寄生虫病学分会, 肝病学分会. 病毒性肝炎防治方案. 中华肝脏病杂志, 2001, 19:56-62. [7] Sarin SK . Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int, 2016, 10:1-98. [8] Martin P , Lau TY , Nguyen MH , et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the united states: 2015 update. Clin Gastroenterol Hepatol, 2015, 13:2071-2087. [9] Van d MAJ , Hansen BE , Fattovich G, et al. Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters. Gut, 2015, 64:322-331. [10] Wai CT, Cheng CL, Wee A,et al. Non-invasive models for predicting histology in patients with chronic hepatitis B. Liver Int, 2006, 26:666-672. [11] 黄盛新, 黎伟, 李雪花,等. 猛老虎汤治疗乙肝肝硬化临床疗效及安全性观察. 辽宁中医杂志, 2019, 46:98-101. [12] 刘洪英, 王艳荣. 复方牛胎肝提取物与拉米夫定联合口服治疗慢性乙型肝炎肝纤维化. 山东医药, 2016, 56:64-66. [13] 余明杰, 王萍, 韩媛媛,等. 肝功能指标及肝纤维化标志物在乙型肝炎患者中的测定意义研究. 中华医院感染学杂志, 2017, 27:41-44. [14] 余明杰, 王萍, 韩媛媛,等. 肝功能指标及肝纤维化标志物在乙型肝炎患者中的测定意义研究. 中华医院感染学杂志, 2017, 27:2912-2915. [15] 吴桐, 常虹, 石松利,等. 蒙古扁桃石油醚提取物对四氯化碳致大鼠肝纤维化的保护作用. 中华中医药学刊, 2017, 35:595-598. |